Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

Lancet

Volumn 356, Issue 9230, 2000, Pages 615-620

  Rouleau, Jean L ^a   Pfeffer, Marc A ^b   Stewart, Duncan J ^c   Isaac, Debra ^d   Sestier, Francois ^e   Kerut, Edmund K ^f   Porter, Charles B ^g   Proulx, Guy ^h   Qian, Chunlin ⁱ   Block, Alan J ⁱ  

^a UNIVERSITY OF TORONTO   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f HEART CLINIC OF LOUISIANA   (United States)

^g UNIVERSITY OF KANSAS HOSPITAL   (United States)

^h MONTREAL HEART INSTITUTE   (Canada)

ⁱ BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; NITRATE; OMAPATRILAT;

ADULT; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEATH; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DYSPNEA; EDEMA; EXERCISE TOLERANCE; FATIGUE; FEMALE; HEADACHE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL INJURY; NAUSEA; NEUROTOXICITY; PARALLEL DESIGN; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THORAX PAIN; TREADMILL EXERCISE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING;

EID: 0034686963     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02602-7     Document Type: Article

References (22)

1. Rouleau J.L. The neurohumoral hypothesis and the treatment of heart failure. Can J Cardiol. 12(suppl F):1996;3-8.
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
3. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 353:1999;9-13.
4. Gohlke P., Linz W., Schölkens B.A.et al. Angiotensin-converting enzyme inhibition improves cardiac function. Hypertension. 23:1994;411-418.
5. Remme W.J. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. Drugs. 54(suppl 5):1997;59-70.
6. Naruse M., Takeyama Y., Tanabe A.et al. Atrial and brain natriuretic peptides in cardiovascular diseases. Hypertension. 23(suppl I):1994;231-234.
7. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med. 339:1998;321-328.
8. Burnett J.C. Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertension. 17(suppl 1):1999;S38-S43.
9. Ikram H., McClean D.R., Mehta S.et al. Long-term beneficial hemodynamic and neurohormonal effects of vasopeptidase inhibition with omapatrilat in heart failure. J Am Coll Cardiol. 32(2 suppl A):1999;185A.
10. Konstam M.A., Kronenberg M.W., Rousseau M.F.et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation. 88:1993;2277-2283.
11. Rouleau J.L., de Champlain J., Klein M.et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol. 22:1993;390-398.
12. Benedict C.R., Johnstone D.E., Weiner D.H.et al. Relation of neurohumoral activation to clinicial variables and degree of ventricular dysfunction. a report from registry of SOLVD J Am Coll Cardiol. 23:1994;1410-1420.
13. Dickstein K. Negative exercise trials in heart failure: result or design? Eur Heart J. 19:1998;1747-1749.
14. Packer M., Bristow W.R., Cohn J.N.et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US carvedilol health failure study group N Engl J Med. 334:1996;1349-1355.
15. Cohn J., Johnson G., Ziesche S.et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
16. DiBianco R., Shabetai R., Kostuk W.et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 320:1989;677-683.
17. Packer M., Carver J.R., Rodeheffer R.J.et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 325:1991;1468-1475.
18. Trippodo N.C., Fox M., Monticello T.M., Panchal B.C., Asaad M.M. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol. 34:1999;782-790.
19. Thomas C.V., McDaniel G.M., Holzgrefe H.H.et al. Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs. J Cardiovasc Pharmacol. 32:1998;902-912.
20. Cavero P.G., Margulies K.B., Winaver J., Seymour A.A., Delaney N.G., Brunett J.C. Jr. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation. 82:1990;196-201.
21. Mitchell G.F., Block A.J., Hartley H.L., Tardif J.C., Rouleau J.L. The vasopeptidase inhibitor, omapatrilat, has a favorable, pressure-independent effect on conduit vessel stiffness in patients with congestive heart failure. Circulation. 100(suppl 1):1999;I-646.
22. Abramson B.L., Ando S., Notarius C.F., Rongen G.A., Floras J.S. Effect of atrial natriuretic peptide on muscle sympathetic activity and its reflex control in human heart failure. Circulaton. 99:1999;1810-1815.